There's lots of pitfalls with this valuation but it's specifically assuming blue sky where all the variables line up with Invex:
- SP appreciates so options are exercised
- Phase 3 is successful - based on Phase 2, I'd put it higher if it's Headache Days since it showed a >7 days improvement in Exenatide which wasn't even reformulated into Presendin.
- And the biggest risk is whether Invex can convince the FDA to go 1 trial - and given they haven't seen the Phase 2 data yet, and with a leading KOI in Professor Sinclair, there is definitely upside if they get it right.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
9.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.839M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 33333 | 9.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.7¢ | 9000 | 1 |
View Market Depth
| Last trade - 16.21pm 07/07/2025 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable